MANKIND - Swing Trade Analysis with AI Signals
Back to ListHere’s the structured swing trade analysis for Mankind Pharma (MANKIND) based on the provided parameters
Swing Trade Rating: 4.1
| Stock Code | MANKIND | Market Cap | 99,392 Cr. | Current Price | 2,406 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 46.8 | Book Value | 397 ₹ | Dividend Yield | 0.04 % | ROCE | 13.6 % |
| ROE | 13.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,328 ₹ | DMA 200 | 2,288 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 732 Cr. | PAT Prev Qtr | 512 Cr. |
| RSI | 55.3 | MACD | 7.50 | Volume | 5,03,393 | Avg Vol 1Wk | 3,53,324 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 2.31 | Debt to equity | 0.34 |
| 52w Index | 60.7 % | Qtr Profit Var | 207 % | EPS | 49.4 ₹ | Industry PE | 32.1 |
📊 Mankind Pharma is trading at ₹2,406, above both 50 DMA (₹2,328) and 200 DMA (₹2,288), showing strong bullish momentum. RSI at 55.3 indicates neutral-to-positive strength, while MACD (7.50) confirms bullish bias. Volumes (5.03L) are higher than weekly averages (3.53L), reflecting strong participation. Valuations are stretched (P/E 46.8 vs industry 32.1), though quarterly PAT growth (₹512 Cr → ₹732 Cr, +207%) supports sentiment. ROCE (13.6%) and ROE (13.7%) are decent, while debt-to-equity at 0.34 remains manageable.
💡 Optimal Entry: ₹2,380–₹2,400 (near support zone)
🚪 Exit if Holding: Profit-taking zone around ₹2,600–₹2,650; Stop-loss below ₹2,350
✅ Positive
- Trading above both 50 DMA and 200 DMA
- Strong quarterly PAT growth (+207%)
- EPS of ₹49.4 supports earnings visibility
- DII holdings increased (+1.20%)
- Healthy trading volumes above weekly average
⚠️ Limitation
- High valuation (P/E 46.8 vs industry 32.1)
- PEG ratio at 2.31 suggests expensive growth valuation
- Dividend yield negligible at 0.04%
- FII holdings decreased (-1.10%)
📉 Company Negative News
- Reduced foreign institutional confidence (-1.10%)
- Valuation pressure due to high P/E
📈 Company Positive News
- Quarterly PAT improved sharply (₹512 Cr → ₹732 Cr)
- DII inflows (+1.20%) show domestic support
🏭 Industry
- Pharma sector average P/E at 32.1, Mankind trades at a premium
- Sector outlook remains positive with consistent demand for healthcare and generics
🔎 Conclusion
Mankind Pharma is a strong candidate for swing trading, supported by robust earnings growth and bullish technicals. Entry near ₹2,380–₹2,400 offers a favorable risk-reward setup, while exits should be considered around ₹2,600–₹2,650. Suitable for short-term momentum trades, though valuations remain stretched.
Would you like me to extend this into a peer comparison with other pharma majors like Sun Pharma or Cipla, or refine it into intraday trading levels for sharper execution?